|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM155173510 |
| 003 |
DE-627 |
| 005 |
20231223071547.0 |
| 007 |
tu |
| 008 |
231223s2005 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0517.xml
|
| 035 |
|
|
|a (DE-627)NLM155173510
|
| 035 |
|
|
|a (NLM)15870017
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Perez, E E
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor
|
| 264 |
|
1 |
|c 2005
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.06.2005
|
| 500 |
|
|
|a Date Revised 27.02.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Peptidomimetics of HIV-1 gp41 sequences required for membrane fusion are potent inhibitors of HIV-1 entry. We hypothesize that expression of a membrane-bound gp41-derived fusion inhibitor will confer HIV-1 resistance to primary CD4 T cells. Efficient gene delivery and stable expression of a membrane-bound gp41-derived fusion inhibitor to primary CD4 T cells was accomplished using a self-inactivating lentiviral vector. A potent antiviral effect was observed when transduced CD4 T cells were challenged with a highly virulent CXCR4-tropic strain of HIV-1. Production of soluble p24 in the supernatant was inhibited 100-fold, and cytopathic effects were evident early in non-transduced cells and absent in transduced cells. Expression of the gp41 sequences was not detrimental to CD4 cells as transduced CD4 T cells exhibited a population doubling time that was equivalent to T cells transduced with a control vector. Results from this study support the rationale to use this lentiviral vector targeted at HIV entry as a potential gene therapy for HIV infection
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Anti-HIV Agents
|2 NLM
|
| 650 |
|
7 |
|a HIV Core Protein p24
|2 NLM
|
| 650 |
|
7 |
|a HIV Envelope Protein gp41
|2 NLM
|
| 650 |
|
7 |
|a HIV Fusion Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Receptors, CXCR4
|2 NLM
|
| 700 |
1 |
|
|a Riley, J L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Carroll, R G
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a von Laer, D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a June, C H
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 115(2005), 1 vom: 01. Apr., Seite 26-32
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:115
|g year:2005
|g number:1
|g day:01
|g month:04
|g pages:26-32
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 115
|j 2005
|e 1
|b 01
|c 04
|h 26-32
|